| abstract |
The invention relates to compounds having a quinazolin-2-one nucleus substituted in the 4-position by alkynyl or alkenyl. They find use in inhibiting non-inverse transcription, including in vivo resistance variants, in the prevention or treatment of infections induced by niv, and for the treatment of spin in the form of compounds or pharmaceutically acceptable salts or of ingredients for pharmaceutical compositions alone and in combination with other antiviral agents, immunostimulants, antibiotics or vaccines. The invention also relates to methods for the treatment of spinoids and for the prevention or treatment of infections induced by niv. |